Immunotherapy in Uncommon and 20ins EGFR-mut Lung Cancers

ClinicalTrials.gov Show glossary Search for terms Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.

Related documents

• Image 2_Case Report: Short-term response to mesenchymal epithelial transition inhibitor/epidermal growth factor receptor tyrosine kinase inhibitor combination in EGFR-mutated non-small cell lung cancer with acquired MET overexpression after progression and discussion on comprehensive management.tif#367124
• Image 1_Case Report: Short-term response to mesenchymal epithelial transition inhibitor/epidermal growth factor receptor tyrosine kinase inhibitor combination in EGFR-mutated non-small cell lung cancer with acquired MET overexpression after progression and discussion on comprehensive management.tif#367123
• Image 3_Case Report: Short-term response to mesenchymal epithelial transition inhibitor/epidermal growth factor receptor tyrosine kinase inhibitor combination in EGFR-mutated non-small cell lung cancer with acquired MET overexpression after progression and discussion on comprehensive management.tif#367121
• Image 4_Case Report: Short-term response to mesenchymal epithelial transition inhibitor/epidermal growth factor receptor tyrosine kinase inhibitor combination in EGFR-mutated non-small cell lung cancer with acquired MET overexpression after progression and discussion on comprehensive management.tif#367122
• IMRT and Timing in Combination With EGFRTKI for Stage IV Non-small-cell Lung Cancer#851528